

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
19 August 2021 (19.08.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/163477 A8

(51) International Patent Classification:

C07K 14/725 (2006.01) C07K 14/82 (2006.01)
A61K 38/17 (2006.01)

tutes of Health, 6701 Rockledge Drive, Suite 700, MSC
7788, Bethesda, Maryland 20892-7788 (US).

(21) International Application Number:

PCT/US2021/017852

(72) **Inventors:** **LEVIN, Noam**; 357 Congressional Lane,
Rockville, Maryland 20852 (US). **PARKHURST, Maria R.**;
4938 Grace Court, Ellicott City, Maryland 21043 (US).
LOWERY, III, Frank J.; 13052 Martz Street, Clarksburg,
Maryland 20871 (US). **ROSENBERG, Steven A.**; 10104
Iron Gate Road, Potomac, Maryland 20854 (US).

(22) International Filing Date:

12 February 2021 (12.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/976,655 14 February 2020 (14.02.2020) US
63/060,340 03 August 2020 (03.08.2020) US

(74) **Agent:** **SPENNER, Jonathan M.** et al.; Leydig, Voit &
Mayer, Two Prudential Plaza, Suite 4900, 180 North Stet-
son Avenue, Chicago, Illinois 60601 (US).

(71) **Applicant:** **THE UNITED STATES OF AMERICA,**
AS REPRESENTED BY THE SECRETARY, DE-
PARTMENT OF HEALTH AND HUMAN SERVICES
[US/US]; Office of Technology Transfer, National Insti-

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,

(54) **Title:** HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION




Figure 3

(57) **Abstract:** Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCRs have antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

[Continued on next page]

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:

29 September 2022 (29.09.2022)

(15) Information about Correction:

see Notice of 29 September 2022 (29.09.2022)